Case report

‘Acute micro-coronary syndrome’: detailed coronary physiology in a patient with Takotsubo cardiomyopathy

Andrew J Morrow, Sabrina Nordin, Patrick O’Boyle, Colin Berry

SUMMARY

Takotsubo cardiomyopathy (TC), otherwise known as stress cardiomyopathy, is characterised by acute, transient left ventricular systolic dysfunction with apical ballooning in the absence of obstructive epicardial coronary stenosis. The presentation of TC mimics that of acute myocardial infarction. More recently there has been a shift towards thinking of TC as a ‘microvascular acute coronary syndrome’. Our case is of an 82-year-old woman who presented with TC mimicking acute anterior ST elevation myocardial infarction in the context of sepsis. Slow flow noted in the left anterior descending artery prompted us to perform coronary physiology. Her fractional flow reserve was 0.91, with an index of myocardial resistance of 117 and a coronary flow reserve of 1.6. In combination these results are indicative of microvascular coronary dysfunction in the absence of significant epicardial stenosis.

BACKGROUND

Takotsubo cardiomyopathy (TC), otherwise known as stress cardiomyopathy, is characterised by acute, transient left ventricular (LV) systolic dysfunction with apical ballooning in the absence of obstructive epicardial coronary stenosis. The name derives from the pathognomonic shape of the ballooned LV on ventriculogram resembling a Japanese octopus trap. Colloquially it is known as ‘broken heart syndrome’ due to its association with acute physical or emotional stress. TC is most prevalent in post-menopausal women, with this group accounting for up to 90% of cases.

The presentation of TC mimics that of acute myocardial infarction, often presenting with chest pain, cardiac enzyme elevation and ischaemic ECG changes (ranging from mild T wave inversion to widespread ST elevation). It accounts for approximately 2% of patients undergoing emergency coronary angiography for acute coronary syndrome.

The pathophysiology of TC is not yet fully understood. The association with emotional and physical stress naturally led investigators towards investigating the role of circulating catecholamines. Patients with TC have increased concentrations of plasma catecholamines that are counterintuitively even higher than those in patients suffering from ST elevation myocardial infarction (STEMI). These levels remain markedly elevated for days after symptom onset. There is ongoing debate regarding the mechanism of how this translates into acute LV dysfunction. One theory suggests direct toxicity of endogenous catecholamine causing myocardial necrosis similar to that observed in acute intracranial haemorrhage. Others suggest that the rapid stimulation of adrenoceptors enhances cardiac inotropy and chronotropy with a secondary oxygen supply-demand imbalance with resultant ischaemia.

More recently there has been a shift towards thinking of TC as a ‘microvascular acute coronary syndrome’. Patients have angiographically slow coronary flow in the absence of epicardial coronary artery stenosis. The cause of this slow flow has been revealed to be acute microvascular impairment. We carried out a literature review using PubMed with the keywords ‘takotsubo’, ‘stress cardiomyopathy’, ‘microvascular’, ‘IMR’ and ‘CFR’. The identified case reports and papers are summarised in Table 1.

This is proposed to relate to primary microvascular coronary spasm mediated by the aforementioned increased concentrations of circulating catecholamines and increased levels of the potent vasoconstrictor endothelin-1 (which preferentially constricts the microcirculation). Intravenous adenosine has been shown to transiently improve myocardial perfusion, wall motion score index and LV ejection fraction in TC but not myocardial infarction, suggesting that microvascular dysfunction plays a major role in the pathogenesis. Microvascular function has been shown to gradually improve with time. This correlates with improving LV function, and both have been shown to normalise at 1-month follow-up.

Additionally, Giusca et al have published a case report of reversible epicardial coronary vasospasm in TC. Although epicardial vasospasm in TC is not commonly reported, this case may suggest the possibility of a spectrum of vasospastic responses, extending from microvascular to epicardial vasospasm in extreme cases.

A recent study has also highlighted the role of inflammation in the pathogenesis of TC. It is currently uncertain whether this inflammation is a primary or secondary process.

CASE PRESENTATION

An 82-year-old woman was referred to her local district general hospital with 3 weeks of worsening left leg cellulitis and confusion. She had a background of hypertension, paroxysmal atrial
fibrillation, corrected hypothyroidism, post-traumatic epilepsy, obesity and chronic bilateral lymphoedema with disseminated secondary eczema. She was clinically septic on arrival—febrile, tachycardic and hypotensive. She was treated with intravenous antibiotics. She was also noted to have an acute kidney injury and delirium. She responded well to initial treatment and avoided the need for inotropic support.

Over the coming week she had physical and biochemical improvement both in her cellulitis and acute kidney injury. Her delirium was slower to resolve and she remained intermittently confused. She was therefore transferred offsite to another district general hospital for a period of convalescence and rehabilitation prior to discharge. She was notably distressed and confused in the context of ongoing delirium and change of treatment team/surroundings.

While in the rehabilitation ward, she developed acute severe chest pain. Her ECG (figure 1) was suggestive of an extensive anterior STEMI. She was discussed with and accepted by her nearest tertiary percutaneous intervention (PCI) centre for anterior STEMI. She proceeded to perform coronary physiology on her LAD

This suggested that, although there was no flow-limiting epicardial coronary stenosis, there was evidence of increased microvascular resistance. A left ventriculogram was then carried out, revealing LV apical ballooning consistent with TC (figure 2B). Her echocardiogram supported the diagnosis of TC, showing evidence of severe LV systolic dysfunction with apical ballooning and akinetic mid to apical regions with preservation of the basal segments (figure 4).

A cardiac MRI (CMR) confirmed severely impaired LV function with akinetic mid to apical LV segments and apical ballooning (figure 5). There was evidence of myocardial oedema

### Table 1

<table>
<thead>
<tr>
<th>Authors</th>
<th>Journal</th>
<th>Year</th>
<th>Evidence of microvascular dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurisu et al</td>
<td>AJCC (Journal of the American College of Cardiology)</td>
<td>2003</td>
<td>Abnormal IMR in all major coronary vessels in 28 patients.</td>
</tr>
<tr>
<td>Bybee et al</td>
<td>AJC (American Journal of Cardiology)</td>
<td>2004</td>
<td>Abnormal TFC in all major coronary vessels in 16 patients.</td>
</tr>
<tr>
<td>Daniels and Fearn</td>
<td>CCI (Catheterization and Cardiovascular Interventions)</td>
<td>2011</td>
<td>Elevation of IMR reported in one case report.</td>
</tr>
<tr>
<td>Layland et al</td>
<td>CRM (Cardiovascular revascularization medicine)</td>
<td>2012</td>
<td>Reversible elevation of IMR in one case report.</td>
</tr>
<tr>
<td>Khalid et al</td>
<td>Int J Cardiol (International Journal of Cardiology)</td>
<td>2015</td>
<td>Corrected TFC in all major coronary vessels in 16 patients.</td>
</tr>
<tr>
<td>Warisawa et al</td>
<td>J Circ (Circulation Journal)</td>
<td>2016</td>
<td>Reversible elevation of IMR in one case report.</td>
</tr>
<tr>
<td>Rivero et al</td>
<td>JAMA Cardiology (Journal of the American Medical Association</td>
<td>2017</td>
<td>Prospective demonstration of time-related improvement of IMR in 15 patients.</td>
</tr>
<tr>
<td>Loffi et al</td>
<td>BioMed Res Int (Biomed research international)</td>
<td>2018</td>
<td>Retrospective analysis of TFC, blush grade and Quantitative myocardial blush score (QUBS) score in 27 patients.</td>
</tr>
</tbody>
</table>

IMR, index of myocardial resistance.

### Table 2

<table>
<thead>
<tr>
<th>Blood test</th>
<th>Reference range, units</th>
<th>t−5 hours</th>
<th>t+0 hour</th>
<th>t+1 hour</th>
<th>t+8 hours</th>
<th>t+17 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Troponin I (0–16, ng/L)</td>
<td>N/A</td>
<td>228</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Troponin T (0–13, ng/L)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Sodium (133–146, mmol/L)</td>
<td>139</td>
<td>138</td>
<td>136</td>
<td>136</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Potassium (3.5–5.3, mmol/L)</td>
<td>3.5</td>
<td>3.2</td>
<td>3.5</td>
<td>4.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea (2.5–7.8, mmol/L)</td>
<td>3.9</td>
<td>4</td>
<td>3.7</td>
<td>3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine (40–130, μmol/L)</td>
<td>71</td>
<td>69</td>
<td>83</td>
<td>94</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilirubin (&lt;20, μmol/L)</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine Aminotransferase (ALT) (&lt;50, UL)</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspartate Aminotransferase (AST) (&lt;40, UL)</td>
<td>14</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Alkaline Phosphatase (ALP) (30–130, U/L)</td>
<td>94</td>
<td>93</td>
<td>78</td>
<td>90</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Albumin (25–50, g/L)</td>
<td>26</td>
<td>25</td>
<td>23</td>
<td>26</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>C reactive protein (0–10, mg/L)</td>
<td>61</td>
<td>59</td>
<td>42</td>
<td>46</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (115–165, g/L)</td>
<td>140</td>
<td>139</td>
<td>130</td>
<td>N/A</td>
<td>137</td>
<td></td>
</tr>
<tr>
<td>White cell count (4.0–10.0, ×109/L)</td>
<td>9.4</td>
<td>9.4</td>
<td>9.37</td>
<td>N/A</td>
<td>9.66</td>
<td></td>
</tr>
<tr>
<td>Neutrophils (2.0–7.0, ×109/L)</td>
<td>4.7</td>
<td>5</td>
<td>4.46</td>
<td>N/A</td>
<td>5.21</td>
<td></td>
</tr>
<tr>
<td>Platelet count (150–410, ×109/L)</td>
<td>321</td>
<td>317</td>
<td>300</td>
<td>N/A</td>
<td>306</td>
<td></td>
</tr>
</tbody>
</table>

T represents the time of onset of chest pain. Highlighted in bold are clinically relevant, abnormal results. N/A, not available.

---

**Figure 1** 12-lead ECG showing ST marked anterior ST elevation (arrows) with Q waves. aVF and aVL, augmented vector F and L.
with elevated native T1 and T2 relaxation times, especially marked in the akinetic mid to apical segments. There was subtle, non-specific epicardial late gadolinium enhancement noted in the LV apex in a non-coronary distribution (figure 6). In combination this pattern is consistent with TC. Additionally, the CMR shows evidence of bilateral pleural effusions and a rim of pericardial fluid indicative of marked cardiac decompensation on presentation.

OUTCOME AND FOLLOW-UP

Our patient returned to her district general hospital the day after her coronary angiogram. There she remained as an inpatient for a further 61 days while undertaking a prolonged programme of intensive rehabilitation due to frailty resulting from her critical illness with sepsis and TC. She ultimately returned to her functional baseline at time of discharge. Unfortunately, 36 days after discharge, she was readmitted with septic shock secondary to severe bilateral bronchopneumonia. She died following a short hospital admission.

She did not have any repeat cardiac imaging following her index admission as she died prior to her appointment for follow-up echocardiogram. We are therefore unable to comment on the degree of residual LV dysfunction at the time of her death.

DISCUSSION

The combination of the above imaging modalities and coronary physiology confirmed the diagnosis of TC. Her trigger appears to have been a combination of physical stress resulting from her sepsis and emotional stress resulting from delirium.

Fractional flow reserve (FFR) is the pressure distal to a coronary stenosis divided by the aortic pressure. It is calculated during hyperaemia (typically pharmacologically induced with adenosine) to minimise vascular resistance to ensure the observed pressure is directly proportional to coronary flow. It represents epicardial coronary flow only. The ischaemic threshold is ≤0.80.16

Coronary flow reserve (CFR) is a measure of coronary vasodilator capacity calculated by the ratio of maximum coronary blood flow to resting coronary blood flow. A pressure/thermistor-tipped guidewire is used to interpret multiple boluses of room temperature intracoronary saline to obtain coronary thermodilution curves and calculate the mean transit times. CFR is a well-established, prognostically validated measure of the vasodilator capacity of the coronary circulation, combining both epicardial and microvascular resistance. CFR may be estimated non-invasively and, as in this case, invasively. CFR may have limited test–retest repeatability and is strongly influenced by resting flow in addition to the response to hyperaemia. Notwithstanding these methodological considerations, the CFR value recorded in our patient (1.6) is severely depressed and very likely to fairly represent substantially depressed vasodilator reserve at that time. In the context of a normal FFR, a low CFR is indicative of microvascular dysfunction. The ischaemic threshold for CFR is ≤2.0.17–19

<table>
<thead>
<tr>
<th>Test</th>
<th>Value</th>
<th>Ischaemic reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting Pd/Pa (distal pressure/aortic pressure)</td>
<td>0.93</td>
<td></td>
</tr>
<tr>
<td>Fractional flow reserve</td>
<td>0.91</td>
<td>&lt;0.8</td>
</tr>
<tr>
<td>Coronary flow reserve</td>
<td>1.6</td>
<td>&lt;2.0</td>
</tr>
<tr>
<td>Index of myocardial resistance</td>
<td>117</td>
<td>&gt;25</td>
</tr>
</tbody>
</table>
Novel diagnostic procedure

The index of myocardial resistance (IMR) is a measure of microvascular resistance. It is defined as the distal coronary pressure divided by the inverse of the hyperaemic mean transit time. It is the minimum microvascular resistance during steady-state, maximum hyperaemia. Unlike CFR, IMR is not influenced by resting conditions. IMR therefore specifically reflects microvascular resistance within a target coronary artery. The normal range of IMR is <25.20 21

All three measurements can be taken quickly in the catheter laboratory using a single pressure/thermistor-tipped guidewire.

The results can then be interpreted together to comment on both epicardial and microvascular coronary function (figure 7). In this case the patient had impaired CFR and IMR with a normal FFR. This is indicative of microvascular dysfunction and is in keeping with the ‘microvascular acute coronary syndrome’ model of TC.

It is generally under-recognised in the medical community that TC is associated with considerable mortality. The International Takotsubo Registry, a consortium of 26 centres in Europe and the USA (n=1750), reported that 9.9% of patients with TC develop acute cardiogenic shock on presentation, with an overall inpatient mortality of 4.1%.22 This is comparable with the outcomes for STEMI in the primary PCI era.23

Current standard of care is the establishment of traditional heart failure medications (ACE inhibitors and beta blockers) without any major randomised control trial (RCT) data to support this. Invasive coronary physiology (FFR/CMR/IMR) may provide an easily assessable, quantitative test of treatment efficacy.

Further research is required to test whether the severity of microvascular dysfunction at diagnosis relates to disease severity or mortality in TC. However the observed simultaneous improvement of coronary flow and LV dysfunction suggests this is an avenue worth exploring.13

Figure 5 Cardiac MRI during systole revealing apical ballooning (arrow) and akinesis with preservation of the basal segments. Bilateral pleural effusions (arrows) reveal the patient’s overloaded fluid status on presentation. LA, left atrium; RA, right atrium.

Figure 6 (A) Late gadolinium enhancement image of an apical four-chamber slice on cardiac MRI showing a subtle, non-specific epicardial late gadolinium enhancement noted in the left ventricular (LV) apex in a non-coronary distribution. (B) T1 map of an apical four-chamber slice on cardiac MRI showing elevated native T1, especially marked in the akinetic mid to apical segments. The native T1 relaxation time in the LV on cardiac MRI showing elevated native T1, especially marked in the non-coronary distribution. (B) T1 map of an apical four-chamber slice on cardiac MRI showing a subtle, non-specific epicardial function. LA, left atrium; RA, right atrium.

Learning points

▶ Takotsubo cardiomyopathy accounts for 2% of all acute coronary syndrome presentations and is associated with similar mortality to that of patients suffering from myocardial infarction in the era of primary percutaneous intervention.
▶ Takotsubo cardiomyopathy is associated with an acute, reversible increase in microvascular resistance that gradually improves with time.
▶ This temporal improvement in microvascular resistance correlates with improving left ventricular function.

Figure 7 Summary of coronary physiology. CFR, coronary flow reserve; FFR, fractional flow reserve; IMR, index of myocardial resistance; Pa, aortic pressure; Pd, distal pressure.

Contributors AJM was responsible for patient consent, appropriating data for publication and drafting the manuscript (both case report and discussion). PO’B, SN and CB jointly conceived the project, performed the reported diagnostic procedure and reviewed the manuscript, with each making critical changes prior to submission. CB was the senior consultant in charge of our patient’s care while in our centre and is the senior author of the paper. All authors have given final approval for the current version to be published.

Funding This study was funded by the British Heart Foundation (grant RE/13/5/30177).

Competing interests CB is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have commercial interests in the diagnosis and treatment of angina. The companies include Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Menarini Pharmaceuticals and Siemens Healthcare.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given,
and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES